Alamar Biosciences, a company focused on the field of proteomics to enable the early detection of cancer and other diseases, and Mologic, a developer of lateral flow and rapid diagnostic tests (RDTs), have collaborated to utilise Alamar’s antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.
Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (“COVIOS” and “COVIGO” for personal self-testing) based on its lateral flow assay technology. Second generation tests with greater sensitivity are now in development leveraging the latest generation of engineered antibodies with ultra-high affinity, discovered through Alamar’s proprietary Attobody platform, together with Mologic’s novel electronic lateral flow immunoassay (eLFIA) technology.
Professor Paul Davis, chief scientific officer & co-founder of Mologic, said: “We are very pleased with the increased sensitivity attainable with Alamar antibodies, especially in view of the speed with which they can be developed. We look forward to continuing our collaboration to create the road map for unprecedented speed of response to new pandemic threats of whatever origin. Fast-track discovery and deployment of antibodies with the highest possible affinity and specificity will be the central pillar of this new Pandemic Preparedness, very much aligning with Mologic’s mission to better enable humanity to cope with the long-term presence of COVID-19.”
Dr. Yuling Luo, founder, chairman & CEO of Alamar, added: “Rapid and highly sensitive COVID-19 detection will remain an essential global health challenge in the coming years, and we must learn from the global COVID-19 experience to ensure a better, robust Pandemic Preparedness. We are excited to continue working with Mologic to meet these needs.”
